Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Technology Scientific & Technical Instruments
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd
Bullboard Posts
User Avatar Image
(5)
•••
Comment by GRAMPS1996on Mar 02, 2017 3:52pm
73 Views
Post# 25922226

RE:The next V.VPT could be V.TLT

RE:The next V.VPT could be V.TLT
opsd1 wrote: They have cured cancer in mice and rats. There were some delays, but they are finally into human clinical trials right now.

Conclusion

Theralase's two-tier operations affords investors exposure to a potentially explosive growth opportunity, while also offering the benefits of a revenue generating, long established business. The company has demonstrated the efficacy of its breakthrough treatment in a mouse and, if the therapy receives FDA approval, could strike a high value partnership with big pharma within two years. Overall, Theralase looks dramatically undervalued at its current market capitalization.
https://www.stockhouse.com/companies/news?symbol=v.tlt


Theralase has Amazing potential IMO
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities